Search results
Merck Reports Progress On The Cancer Front As It Prepares For Keytruda Patent Expiration
Benzinga via AOL· 5 days agoMerck reported improvement in cancer patients receiving its Keytruda regimen. Enrolling 698...
Merck's KEYTRUDA shows survival benefit in gastric cancer trial By Investing.com
Investing.com· 6 days agoMerck & Co., Inc., a leading pharmaceutical company, announced positive results from the Phase 3...
Jemperli contends with blockbuster Keytruda in endometrial cancer
Clinical Trials Arena via Yahoo Finance· 6 days agoThe sBLA approval is based on the success of the Phase III RUBY Part I trial and places Jemperli in...
Merck reports data from Phase III gastric cancer treatment trial
Clinical Trials Arena via Yahoo Finance· 5 days agoMerck (MSD) has announced the final analysis findings from the Phase III KEYNOTE-811 clinical trial...
Dow Jones Drug Giant Merck, Nvidia Eye Buy Points In Current Stock Market
Investor's Business Daily· 15 hours agoMerck stock backstory: On April 25, Merck jumped after the Dow Jones stalwart topped Wall Street's...
Is Merck Stock Fully Valued At $130?
Forbes· 6 days agoMerck (NYSE: MRK) recently reported its Q1 results, with revenues and earnings exceeding our estimates. The growth was primarily driven by higher sales...
3 Investing Pros Lay Out Their Dividend Strategies—and Stock Picks
Barrons.com· 5 days agoIn February, Walmart announced a 9% dividend increase, its largest in more than a decade. Another of...
Here's Why Merck (MRK) is a Strong Momentum Stock
Zacks via Yahoo Finance· 4 days agoWhether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks...
CG follows big IPO with new results for bladder cancer drug
BioPharma Dive via Yahoo Finance· 4 days agoNewly disclosed Phase 3 results presented Friday match findings the biotech disclosed last year,...
Moderna plants new solid tumor trials for cancer vaccine, weeds PD-1 work after review
FierceBiotech· 5 days agoModerna detailed plans for its individual neoantigen cancer vaccine in a first-quarter earnings...